vinorelbine (Rx)

Brand and Other Names:Navelbine
  • Print

Dosing & Uses


Dosage Forms & Strengths

injectable solution

  • 10mg/1mL
  • 50mg/5mL

Non-small Cell Lung Cancer


  • Indicated for metastatic non-small cell lung cancer (NSCLC)
  • 30 mg/m² IV infused over 6-10 minutes qWeek  

Combination therapy

  • Indicated in combination with cisplatin for first-line treatment of locally advanced or metastatic NSCLC
  • 25 mg/m² IV qWeek on Days 1, 8, 15, and 22 of a 28-day cycle with IV cisplatin 100 mg/m² on Day 1 OR
  • 30 mg/m² IV qWeek with cisplatin 120 mg/m² IV on Days 1 and 29, and then q6Weeks

Dosage Modifications

Neutrophils on day of treatment

  • >1500 cells/mm³: 100 % of dose
  • 1000-1499 cells/mm³: Decrease dose 50%
  • <1000 cells/mm³: Do not administer; repeat neutrophil count in 1 week
  • If 3 consecutive weekly doses are held owing to neutrophils <1000 cell/mm³, discontinue
  • Fever or sepsis while neutrophil count <1500 or dose held for 2 weeks
    • >1500 cells/mm³: 75% of dose
    • 1000-1499 cells/mm³: 37.5% of dose
    • <1000 cells/mm³: Do not administer; repeat neutrophil count in 1 week


  • Grade ≥2: Discontinue

Renal impairment

  • Dose adjustment not necessary

Hepatic impairment or toxicity

  • Total bilirubin (TB) <2 mg/dL: Dose adjustment not necessary
  • TB 2.1-3 mg/dL: Decrease dose 50%
  • TB >3 mg/dL: Decrease dose 75%

Breast Cancer (Off-label)

20-30 mg/m² qWeek, has been administered as IV infusion, slow (3-5 minutes) or rapid IV injection  

Ovarian Cancer (Off-label)

25 mg/m² q7Days  

25-30 mg/m²/day on days 1 & 8 of 21 day cycle

Soft Tissue Sarcoma (Orphan)

Liposomal vinorelbine

Orphan designation for treatment of soft tissue sarcoma


  • Taiwan Liposome Company, Ltd; 3 Yuanqu Street; Taiwan

Safety and efficacy not established



Interaction Checker

and vinorelbine

No Results

     activity indicator 
    No Interactions Found
    Interactions Found


      Serious - Use Alternative

        Significant - Monitor Closely


            All Interactions Sort By:
             activity indicator 

            Adverse Effects


            Leukopenia (92%)

            Granulocytopenia (90%)

            Anemia (83%)

            Elev AST (67%)

            Nausea (44%)

            Asthenia (36%)

            Constipation (35%)

            Fatigue (27%)

            Peripheral neuropathy (25%)

            Vomiting (20%)

            Anorexia (20%)

            Stomatitis (20%)

            Alopecia (12%)


            Dyspnea (7%)

            Chest pain (5%)

            Rash (5%)

            SOB (3%)

            Hemorrhagic cystitis (1%)

            SIADH (1%)

            Postmarketing Reports

            Palmar-plantar erythrodysesthesia syndrome

            Hepatic toxicity

            Bowel obstruction

            Pulmonary toxicity

            Respiratory failure



            Black Box Warnings

            Severe myelosuppression resulting in serious infection, septic shock, hospitalization and death can occur

            Decrease and/or withhold dose in accord with recommended dose modifications




            Myelosuppression, manifested by neutropenia, anemia, and thrombocytopenia reported; neutropenia is the major dose-limiting toxicity; monitor complete blood counts before each dose

            Risk of extravasation and tissue injury

            Sensory and motor neuropathies reported

            Can cause fetal harm if administered to pregnant women based on findings from animal studies and mechanism of action

            Hepatic toxicity

            • Drug-induced liver injury manifested by elevated aspartate aminotransferase (AST) and bilirubin occur in patients receiving drug as single agent and in combination with cytotoxic agents
            • Assess hepatic function prior to initiation of therapy and periodically during treatment
            • Reduce dose for patients who develop elevations in total bilirubin greater than or equal to 2 times upper limit of normal

            Gastrointestinal effects

            • Severe and fatal paralytic ileus, constipation, intestinal obstruction, necrosis, and perforation reported
            • Institute a prophylactic bowel regimen to mitigate potential constipation, bowel obstruction and/or paralytic ileus
            • Consider adequate dietary fiber intake, hydration and routine use of stool softeners

            Pulmonary toxicity

            • Pulmonary toxicity, including severe acute bronchospasm, interstitial pneumonitis, acute respiratory distress syndrome (ARDS) occur in patients receiving therapy
            • Interrupt therapy in patients who develop unexplained dyspnea or have any evidence of pulmonary toxicity
            • Permanently discontinue therapy for confirmed interstitial pneumonitis or ARDS

            Preparation in IV infusion bag only

            • On January 15, 2021, FDA alerted that vinca alkaloids should be prepared in IV infusion bags only
            • Intrathecal (IT) administration will result in severe neurological injury and/or death
            • Label update is to reduce the potential for unintended IT administration

            Pregnancy & Lactation


            Based on animal findings, can cause fetal harm when administered to pregnant women

            Verify pregnancy status in females of reproductive potential before initiating

            Animal studies

            • In animal reproduction studies in mice and rabbits, embryo and fetal toxicity were observed with vinorelbine doses ~0.33 and 0.18 times the human therapeutic dose, respectively


            • Females: Use effective contraception during treatment and for 6 months after final dose
            • Males: May damage spermatozoa; advise males with female sexual partners of reproductive potential to use effective contraception during treatment and for 3 months after final dose


            • Males: Based on animal findings, may impair fertility


            Data are not available regarding drug in human milk or effects on breastfed infant or milk production

            Because of potential harm; advise women not to breastfeed during treatment and for 9 days after final dose

            Pregnancy Categories

            A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

            B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

            C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

            D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

            X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

            NA: Information not available.



            Mechanism of Action

            Semi-synthetic vinca alkaloid; inhibits mitosis at metaphase by depolymerizing microtubules; specific for S ans M phases; may also inhibit nucleic acid and protein synthesis by blocking glutamic acid use


            Half-Life: 28-44 hr

            Peak Plasma: 234-1160 ng/mL

            Plasma clearance: 0.97-1.26 L/hr/kg

            Protein Bound: 80-92%

            Vd: 25-40 L/kg

            Metabolism: CYP3A isoenzymes

            Metabolites: vinorelbine N-oxide, deacetylvinorelbine

            Clearance: 0.97-1.26 L/hr/kg

            Excretion: Feces (46%); urine (18%)



            IV Incompatibilities

            Y-site: acyclovir, allopurinol, aminophylline, amphotericin B, ampho B cholesteryl sulfate, ampicillin, cefazolin, cefoperazone, cefotetan, ceftriaxone, cefuroxime, co-trimoxazole, fluorouracil, furosemide, ganciclovir, methylprednisolone sodium succinate, mitomycin, piperacillin, sodium bicarbonate, thiotepa

            IV Compatibilities


            • D5W
            • 0.9% NaCl
            • 0.45% NaCl
            • D5W 0.45% NaCl
            • Lactated Ringer (LR)
            • Ringer’s

            Y-site (partial list)

            • Buprenorphine, cisplatin, cyclophosphamide, diphenhydramine, gemcitabine, fluconazole, granisetron, hydromorphone, imipenem-cilastatin, lorazepam, meperidine, morphine, ondansetron, KCl, vancomycin, zidovudine

            IV Preparation

            Prepare in infusion bag only

            Dilute to 0.5-2 mg/mL in 0.9% NaCl, 0.45% NaCl, D5W, D5/0.45% NaCl, LR or Ringer's

            IV Administration


            For IVPB use only; fatal if given intrathecally

            Always properly position IV needle or catheter before any infusion

            Infuse over 6-10 min through sidearm of free-flowing IV closest to IV bag

            Flush with 75-125 mL of one of the IV compatible fluids

            Extravasation Management

            Mix 250 U hyaluronidase with 6 mL NS

            Inject hyaluronidase solution subcutaneously through 6 clockwise injections into infiltrated area using a 25-gauge needle

            Change needle with each new injection

            Elevate extremities

            Apply heat immediately for 1 hr

            Give QID for 3-5 days

            Application of cold or hydrocortisone is contraindicated


            Unopened vials: Refrigerate; protected from light

            Diluted solution: Store for 24 hr under normal light at 5-30ºC





            FormularyPatient Discounts

            Adding plans allows you to compare formulary status to other drugs in the same class.

            To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

            Adding plans allows you to:

            • View the formulary and any restrictions for each plan.
            • Manage and view all your plans together – even plans in different states.
            • Compare formulary status to other drugs in the same class.
            • Access your plan list on any device – mobile or desktop.

            The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

            Tier Description
            1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
            2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
            3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
            4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            NC NOT COVERED – Drugs that are not covered by the plan.
            Code Definition
            PA Prior Authorization
            Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
            QL Quantity Limits
            Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
            ST Step Therapy
            Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
            OR Other Restrictions
            Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
            Additional Offers
            Email to Patient



            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Email Forms to Patient



            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.